CELL MEDIATED IMMUNITY IN PATIENTS WITH STAGE II–IV COLORECTAL CANCER WITH OR WITHOUT CIRCULATING TUMOR CELLS
https://doi.org/10.21294/1814-4861-2020-19-4-94-98
Abstract
Nowadays, circulating tumor cells (CTCs) are considered to be one of the most important mechanisms of tumor dissemination. Detection of CTCs in patients` blood is estimated as a prognostic factor for various tumors including colorectal cancer (CRC). However, CTCs may also be a source of tumor antigens capable of inducing both immune response and tolerance and participating in «immmunoediting».
The aim of the study was to assess the parameters of cell-mediated immunity in patients with stage IIIV CRC with respect to the presence or absence of CTCs.
Materials and Methods. We studied the parameters of cell-mediated immunity in 60 patients with stage IIIV CRC with respect to the presence or absence of CTCs. Before treatment, we evaluated the CTC levels in patients’ blood using CellSearch System™ and lymphocyte subsets: Т-В-NК-cells, T-reg, CD4+ and CD8+ expressing markers of activation (CD69+, СD38+, CD25+, HLA-DR+ СD95+); naïve and memory T-lymphocytes (CD45RA-/CD45RO+); NК-cells expressing CD335, perforin and granzyme B using flow cytometry (FACSCantoII, BD).
Results. A difference in the immunologic parameters between patients with CTCs and without CTCs depending on the stage of CRC was found. In СTС-positive patients with locally-advanced CRC, increase in the parameters of innate immunity (CD335+ NK-cells, neutrophils` respiratory burst) and activated Th (CD38+, CD25+, HLA-DR+) was found, while in СTС-positive patients with generalized CRC, suppression of cytotoxic lymphocytes of both innate (CD56/16+) and adaptive (CD8+CD25+) immunity was observed, which is, apparently, an unfavorable prognostic factor.
Conclusion. The presence of CTC in CRC patients is accompanied by some immunologic changes rather stimulating Thlink and innate immunity factors in II-III stages and doubtlessly suppressive in patients with IV stage.
The aim of the study was to assess the parameters of cell-mediated immunity in patients with stage IIIV CRC with respect to the presence or absence of CTCs.
Materials and Methods. We studied the parameters of cell-mediated immunity in 60 patients with stage IIIV CRC with respect to the presence or absence of CTCs. Before treatment, we evaluated the CTC levels in patients’ blood using CellSearch System™ and lymphocyte subsets: Т-В-NК-cells, T-reg, CD4+ and CD8+ expressing markers of activation (CD69+, СD38+, CD25+, HLA-DR+ СD95+); naïve and memory T-lymphocytes (CD45RA-/CD45RO+); NК-cells expressing CD335, perforin and granzyme B using flow cytometry (FACSCantoII, BD).
Results. A difference in the immunologic parameters between patients with CTCs and without CTCs depending on the stage of CRC was found. In СTС-positive patients with locally-advanced CRC, increase in the parameters of innate immunity (CD335+ NK-cells, neutrophils` respiratory burst) and activated Th (CD38+, CD25+, HLA-DR+) was found, while in СTС-positive patients with generalized CRC, suppression of cytotoxic lymphocytes of both innate (CD56/16+) and adaptive (CD8+CD25+) immunity was observed, which is, apparently, an unfavorable prognostic factor.
Conclusion. The presence of CTC in CRC patients is accompanied by some immunologic changes rather stimulating Thlink and innate immunity factors in II-III stages and doubtlessly suppressive in patients with IV stage.
About the Authors
E. Y. Zlatnik
Rostov Research Institute of Oncology
Russian Federation
Russian Federation
Elena Y. Zlatnik, MD, Professor, Chief Researcher, Laboratory of Immunophenotyping of Tumors
Author ID (Scopus): 6603160432
63, 14-th Liniya Street, 344037, Rostov-on-Don
A. O. Sitkovskaya
Rostov Research Institute of Oncology
Russian Federation
Russian Federation
Anastasia O. Sitkovskaya, Researcher, Laboratory of Cellular Technologies
Researcher ID (WOS): E-7496-2018. Author ID (Scopus): 56381527400.
63, 14-th Liniya Street, 344037, Rostov-on-Don
I. A. Novikova
Rostov Research Institute of Oncology
Russian Federation
Russian Federation
Inna A. Novikova, PhD, Deputy General Director for Science
Researcher ID (WOS): E-7710-2018. Author ID (Scopus): 7005153343.
63, 14-th Liniya Street, 344037, Rostov-on-Don
E. S. Bondarenko
Rostov Research Institute of Oncology
Russian Federation
Russian Federation
Elena S. Bondarenko, Junior Researcher, Laboratory of Immunophenotyping of Tumors
Author ID (Scopus): 57200132337.
63, 14-th Liniya Street, 344037, Rostov-on-Don
A. B. Sagakyants
Rostov Research Institute of Oncology
Russian Federation
Russian Federation
Alexander B. Sagakyants, PhD, Associate Professor, Head of Laboratory of Tumor Immunophenotyping
Researcher ID (WOS): M-8378-2019. Author ID (Scopus): 24329773900
63, 14-th Liniya Street, 344037, Rostov-on-Don
References
1. Mittal D., Gubin M.M., Schreiber R.D., Smyth M.J. New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape. Curr Opin Immunol. 2014; 27: 16–25. doi: 10.1016/j.coi.2014.01.004.
2. Kitamura T., Qian B.Z., Pollard J.W. Immune cell promotion of metastasis. Nat Rev Immunol. 2015 Feb; 15(2): 73–86. doi: 10.1038/nri3789.
3. Kit O.I., Novikova I.A., Nikipelova E.A., Nistratova O.V., Bachtin A.V., Selutina O.V., Chernikova E.N. Circulating tumor cell as a highly specific prognostic factors. Review of the literature. International Journal of Applied and Fundamental Researchs. 2014; 12(2): 252–257. (in Russian).
4. Bidard F.C., Peeters D.J., Fehm T., Nolé F., Gisbert-Criado R., Mavroudis D., Grisanti S., Generali D., Garcia-Saenz J.A., Stebbing J., Caldas C., Gazzaniga P., Manso L., Zamarchi R., de Lascoiti A.F., De Mattos-Arruda L., Ignatiadis M., Lebofsky R., van Laere S.J., Meier-Stiegen F., Sandri M.T., Vidal-Martinez J., Politaki E., Consoli F., Bottini A., Diaz-Rubio E., Krell J., Dawson S.J., Raimondi C., Rutten A., Janni W., Munzone E., Carañana V., Agelaki S., Almici C., Dirix L., Solomayer E.F., Zorzino L., Johannes H., Reis-Filho J.S., Pantel K., Pierga J.Y., Michiels S. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: A pooled analysis of individual patient data. Lancet Oncol. 2014; 15: 406–14. doi:10.1016/S1470-2045(14)70069-5.
5. Burz C., Pop V.V., Buiga R., Daniel S., Samasca G., Aldea C., Lupan I. Circulating tumor cells in clinical research and monitoring patients with colorectal cancer. Oncotarget. 2018; 9(36): 24561–71. doi: 10.18632/oncotarget.25337.
6. Nepomnyashchaya E.M., Kit O.I., Nistratova O.V., Novikova I.A., Nikipelova E.A., Bakhtin A.V., Ulyanova E.P., Vostrikova Zh.I., Selyutina O.N. Circulating tumor cells and some morphoimmunohistochemical parameters in colorectal cancer. Modern problems of science and education. 2016; 2 [Internet]. URL: http://www.scienceeducation.ru/ru/article/view?id=24378 (cited 28.05.2020). (in Russian).
7. Mego M., Gao H., Cohen E.N., Anfossi S., Giordano A., Sanda T., Fouad T.M., De Giorgi U., Giuliano M., Woodward W.A., Alvarez R.H., Valero V., Ueno N.T., Hortobagyi G.N., Cristofanilli M., Reuben J.M. Circulating Tumor Cells (CTC) Are Associated with Defects in Adaptive Immunity in Patients with Inflammatory Breast Cancer. J Cancer. 2016 Jun 3; 7(9): 1095–104. doi: 10.7150/jca.13098.
8. Leone K., Poggiana C., Zamarchi R. The Interplay between Circulating Tumor Cells and the Immune System: From Immune Escape to Cancer Immunotherapy. Diagnostics (Basel). 2018 Aug 30; 8(3): 59. doi: 10.3390/diagnostics8030059.
9. Manina I.V., Saprikina N.S., Kozlov A.M., Mikhaylova I.N., Grigorieva I.N., Kasatkina N.N., Barishnikov A.Y. The increasing of gm -csf produced vaccine efficiency by inhibition the cells with cytokines. Russian Journal of Biotherapy. 2011; 3: 61–66. (in Russian).
10. Ermakova N.P., Mikhaylova I.N., Merkulova I.B., Konyaeva O.I., Kulbachevskaya N.Yu., Abramova T.V., Baryshnikov K.A., Mikhaylova L.M. Re-clinical study of anticancer vaccine «Melovac» toxicity. Russian Journal of Biotherapy. 2010; 1: 57–62. (in Russian).
11. Bakhtin A.V., Kit O.I., Novikova I.A., Zlatnik E.Yu., Isaeva R.G., Selyutina O.N., Shulgina O.G. Detection of tumor cells circulating in the blood and their relationship with immunocompetent cells in patients with generalized forms of lung cancer. Modern Problems of Science and Education. 2015; 3 [Internet]. URL: https://www.science-education.ru/ru/article/view?id=19734 (cited 28.05.2020). (in Russian).
12. Ye L., Zhang F., Li H., Yang L., Lv T., Gu W., Song Y. Circulating Tumor Cells Were Associated with the Number of T Lymphocyte Subsets and NK Cells in Peripheral Blood in Advanced Non-Small-Cell Lung Cancer. Dis Markers. 2017; 2017: 5727815. doi: 10.1155/2017/5727815.
13. Green T.L., Cruse J.M., Lewis R.E., Craft B.S. Circulating tumor cells (CTCs) from metastatic breast cancer patients linked to decreased immune function and response to treatment. Exp Mol Pathol. 2013 Oct; 95(2): 174–9. doi: 10.1016/j.yexmp.2013.06.013.
14. Schölch S., Bork U., Rahbari N.N., García S., Swiersy A., Betzler A.M., Weitz J., Koch M. Circulating tumor cells of colorectal cancer. Cancer Cell Microenvironment. 2014; 1: e323. doi: 10.14800/ccm.323.
Review
For citations:
Zlatnik E.Y., Sitkovskaya A.O., Novikova I.A., Bondarenko E.S., Sagakyants A.B. CELL MEDIATED IMMUNITY IN PATIENTS WITH STAGE II–IV COLORECTAL CANCER WITH OR WITHOUT CIRCULATING TUMOR CELLS. Siberian journal of oncology. 2020;19(4):94-98. (In Russ.) https://doi.org/10.21294/1814-4861-2020-19-4-94-98
Views:
958
Email this article 
